LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LDX

LDX - LUMOS DIAGNOSTICS HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.5
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.10

27 Aug
2026

-0.005

OPEN

$0.11

-4.76%

HIGH

$0.11

2,533,334

LOW

$0.10

TARGET
$0.25 150.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
LDX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 0.9 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx19.5 M
Book Value Per Share xxxxxxxxxxxxxxx3.5
Net Operating Cash Flow xxxxxxxxxxxxxxx1.5 M
Net Profit Margin xxxxxxxxxxxxxxx-37.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-34.48 %
Return on Invested Capital xxxxxxxxxxxxxxx-24.99 %
Return on Assets xxxxxxxxxxxxxxx-16.14 %
Return on Equity xxxxxxxxxxxxxxx-34.48 %
Return on Total Capital xxxxxxxxxxxxxxx-67.67 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-2.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx7 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.01

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx3.7 M
Capex % of Sales xxxxxxxxxxxxxxx19.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx31 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/08/2026

1

Speculative Buy

$0.25

150.00%

Bell Potter retains its Buy rating on point-of-care (POC) diagnostics company Lumos Diagnostics with an unchanged 25c target following a better-than-expected FY26 result.

The FY26 adjusted earnings (EBITDA) loss of -US$2.8m was better than the broker's -US$5.3m forecast due to lower operating expenses.

FebriDx sales have commenced strongly, observe the analysts, with the test now used across 170 sites in 24 US states. FebriDx is a rapid point-of-care blood test designed to help determine whether an acute respiratory infection is likely viral or bacterial.

Bell Potter expects the US flu season and further urgent care contracts to drive a material increase in FebriDx orders in FY27.

FY27-FY29 earnings loss forecasts deteriorate by -38%, -67% and -37%, respectively, reflecting higher commercial rollout costs, the analysts explain.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.20 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

LDX STOCK CHART

FNArena News on LDX

1
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia
2
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
3
Australian Broker Call *Extra* Edition – Mar 21, 2023

Mar 21 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 06, 2022

Sep 06 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 10, 2022

Aug 10 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals